English

Directory | Consumers | FAQ

Increase size

Reset to Default

Decrease size

NPRA Banner

Approved Clinical Trial Import License & Clinical Trial Exemption (CTX) Application

: Posted By Nur Atiqah Kamal Rodin; 18 November 2025; Hits: 52059

User Rating: 4 / 5

Document Name	PDF
Status Kelulusan Permohonan CTIL/CTX Bulan April- Disember 2020	2020
Status Kelulusan Permohonan CTIL/CTX Tahun 2021	2021
Status Kelulusan Permohonan CTIL/CTX Tahun 2022	2022
Status Kelulusan Permohonan CTIL/CTX Tahun 2023	2023
Status Kelulusan Permohonan CTIL/CTX Tahun 2024	2024
Status Kelulusan Permohonan CTIL/CTX Bulan Jan - Oktober 2025	JAN - OKT 2025

Additional Indications Approved

: Posted By Seksyen Koordinasi Regulatori Produk & Kosmetik; 12 November 2025; Hits: 159817

User Rating: 3 / 5

Approved Additional Indication DCA 414

Approved Additional Indication DCA 413

Approved Additional Indication DCA 412

Approved Additional Indication DCA 411

Approved Additional Indication DCA 410

Approved Additional Indication DCA 409

Approved Additional Indication DCA 408

Approved Additional Indication DCA 407

Approved Additional Indication DCA 406

Approved Additional Indication DCA 405

Approved Additional Indication DCA 404

Approved Additional Indication DCA 403

Approved Additional Indication DCA 402

Approved Additional Indication DCA 401

Approved Additional Indication DCA 400

Approved Additional Indication DCA 399

Approved Additional Indication DCA 398

Approved Additional Indication DCA 397

Approved Additional Indication DCA 396

Approved Additional Indication DCA 395

Approved Additional Indication DCA 394

Approved Additional Indication DCA 393

Approved Additional Indication DCA 391

Approved Additional Indication DCA 390

Approved Additional Indication DCA 389

Approved Additional Indication DCA 388

Approved Additional Indication DCA 387

Approved Additional Indication DCA 386

Approved Additional Indication DCA 385

Approved Additional Indication DCA 384

Approved Additional Indication DCA 383

Approved Additional Indication DCA 382

Approved Additional Indication DCA 381

Approved Additional Indication DCA 380

Approved Additional Indication DCA 379

Approved Additional Indication DCA 378

Approved Additional Indication DCA 377

Approved Additional Indication DCA 376

Approved Additional Indication DCA 375

Approved Additional Indication DCA 374

Approved Additional Indication DCA 373

Approved Additional Indication DCA 372

Approved Additional Indication DCA 371

Approved Additional Indication DCA 370

Approved Additional Indication DCA 369

Approved Additional Indication DCA 368

Approved Additional Indication DCA 367

Approved Additional Indication DCA 366

Approved Additional Indication DCA 365

Approved Additional Indication DCA 364

Approved Additional Indication DCA 363

Approved Additional Indication DCA 362

Approved Additional Indication DCA 360

Approved Additional Indication DCA 359

Approved Additional Indication DCA 358

Approved Additional Indication DCA 357

Approved Additional Indication DCA 355

Approved Additional Indication DCA 354

Approved Additional Indication DCA 353

Approved Additional Indication DCA 352

Approved Additional Indication DCA 351

Approved Additional Indication DCA 350

Approved Additional Indication DCA 349

Approved Additional Indication DCA 348

Approved Additional Indication DCA 347

Approved Additonal Indication DCA 346

Approved Additional Indication DCA 344

Approved Additional Indication DCA 343

Approved Additional Indication DCA 342

Approved Additional Indication DCA 341

Approved Additional Indication DCA 340

Approved Additional Indication DCA 339

Approved Additional Indication DCA 338

Approved Additional Indication DCA 337

Approved Additional Indication DCA 336

Approved Additional Indication DCA 335

Approved Additional Indication DCA 334

Approved Additional Indication DCA 333

Approved Additional Indication DCA 332

Approved Additional Indication DCA 331

Approved Additional Indication DCA 330

Approved Additional Indication DCA 329

Approved Additional Indication DCA 328

Approved Additional Indication DCA 327

Approved Additional Indication DCA 326

Approved Additional Indication DCA 324

Approved Additional Indication DCA 323

Approved Additional Indication DCA 322

Approved Additional Indication DCA 321

Approved Additional Indication DCA 320

Approved Additional Indication DCA 319

Approved Additional Indication DCA 318

Approved Additional Indication DCA 317

Approved Additional Indication DCA 316

Approved Additional Indication DCA 315

Approved Additional Indication DCA 314

Approved Additional Indication DCA 313

Approved Additional Indication DCA 312

Approved Additional Indication DCA 310

Approved Additional Indication DCA 308

Approved Additional Indication DCA 307

Approved Additional Indication DCA 306

Approved Additional Indication DCA 305

Approved Additional Indication DCA 304

Approved Additional Indication DCA 303

Approved Additional Indication DCA 301

Approved Additional Indication DCA 300

Approved Additional Indication DCA 299

Approved Additional Indication DCA 295

Approved Additional Indication DCA 294

Approved Additional Indication DCA 293

Approved Additional Indication DCA 292

Approved Additional Indication DCA 291

Approved Additional Indication DCA 290

Approved Additional Indication DCA 289

Approved Additional Indication DCA 288

Approved Additional Indication DCA 287

Approved Additional Indication DCA 286

Approved Additional Indication DCA 284

Approved Additional Indication DCA 283

Approved Additional Indication DCA 282

Approved Additional Indication DCA 281

Approved Additional Indication DCA 280

Approved Additional Indication DCA 279

Approved Additional Indication DCA 277

Approved Additional Indication DCA 275

Approved Additional Indication DCA 274

Approved Additional Indication DCA 273

Approved Additional Indication DCA 272

Approved Additional Indication DCA 271

Approved Additional Indication DCA 269

Approved Additional Indication DCA 268

Approved Additional Indication DCA 267

Approved Additional Indication DCA 266

Approved Additional Indication DCA 265

Approved Additional Indication DCA 264

Approved Additional Indication DCA 263

Approved Additional Indication DCA 262

Approved Additional Indication DCA 261

Approved Additional Indication DCA 260

Approved Additional Indication DCA 259

Approved Additional Indication DCA 258

Approved Additional Indication DCA 257

Approved Additional Indication DCA 256

Approved Additional Indication DCA 253

Approved Additional Indication DCA 252

Approved Additional Indication DCA 250

Approved Additional Indication DCA 248

Additional Indications Approved / Archives

New Products Approved

: Posted By Seksyen Koordinasi Regulatori Produk & Kosmetik; 06 November 2025; Hits: 389325

User Rating: 3 / 5

Year 2025

Year 2024

Year 2023

Year 2022

Year 2021

Year 2020

Year 2019

Year 2018

Year 2017

DCA318 (Manual)

New Products Approved Archived

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

Phone: +603-7883 5400

More Links

Privacy & Policy

More Links

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

Last Modified: Friday 05 December 2025, 15:47:32.

Online Services

NPRA Support System

Online Public Engagement

Online Procurement Announcement